Our Pricing

Mysimba vs Ozempic UK Comparison: Which Weight Loss Treatment Is Right for You?

When evaluating a mysimba vs ozempic uk comparison, you're weighing two fundamentally different approaches to weight management: oral tablets versus injectable medication. At Cured Pharmacy, our UK-registered clinical team helps patients navigate this choice with transparent pricing, expert guidance, and access to clinically proven alternatives including Wegovy (semaglutide). All prescription weight loss treatments require assessment by a UK prescriber to ensure safety and suitability.

Understanding Mysimba: How Naltrexone-Bupropion Tablets Work

Mysimba combines two active ingredients—naltrexone (8mg) and bupropion (90mg)—in a single tablet taken twice daily. This combination works centrally in the brain to reduce appetite and food cravings by modulating reward pathways and hunger signals [1]. Unlike GLP-1 receptor agonists, Mysimba doesn't directly affect gut hormones or slow gastric emptying.

In the COR-I clinical trial, patients taking Mysimba alongside lifestyle interventions achieved an average weight loss of 6.1% over 56 weeks, compared to 1.3% with placebo [1]. The medication requires gradual dose escalation over four weeks to minimise side effects, reaching the full maintenance dose of two tablets twice daily.

Mysimba is contraindicated in patients with uncontrolled hypertension, seizure disorders, eating disorders, or those taking certain antidepressants or opioid medications. Your UK prescriber will conduct a thorough medical assessment before determining suitability, as these interactions require careful clinical evaluation.

Ozempic Single Pen: Semaglutide Injection Mechanism

Ozempic contains semaglutide, a GLP-1 (glucagon-like peptide-1) receptor agonist originally licensed for type 2 diabetes management. The single pen delivers once-weekly subcutaneous injections in escalating doses: 0.25mg for four weeks, then 0.5mg, with potential increases to 1mg or 2mg based on clinical response [2].

Semaglutide mimics a natural gut hormone that regulates blood sugar, slows stomach emptying, and reduces appetite through central nervous system pathways. In the STEP 1 trial, participants using semaglutide 2.4mg (the Wegovy formulation) achieved average weight loss of 14.9% over 68 weeks—significantly higher than naltrexone-bupropion combinations [2][3].

While Ozempic pens are primarily prescribed for diabetes, many UK patients seek semaglutide specifically for weight management. Wegovy, which contains the same active ingredient at weight-loss-optimised doses, represents the MHRA-licensed option for obesity treatment and is available at Cured Pharmacy from £79.00 subject to prescriber approval.

Injectable vs Oral: Practical Considerations

The route of administration significantly impacts patient adherence and lifestyle fit. Mysimba requires twice-daily oral dosing with food, demanding consistent routine and pill-taking discipline. Ozempic and Wegovy require only once-weekly injections using pre-filled pens with fine needles (32G), which most patients find straightforward after initial training from their pharmacist.

Mysimba vs Ozempic UK: Clinical Efficacy Comparison

Direct head-to-head trials between naltrexone-bupropion and semaglutide are limited, but individual trial data reveals substantial differences in weight loss magnitude. Mysimba trials consistently show average reductions of 5-7% body weight, whilst semaglutide formulations demonstrate 12-15% average reductions in clinical populations [1][2][3].

GLP-1 receptor agonists like semaglutide also provide additional metabolic benefits including improved glycaemic control, reduced cardiovascular risk markers, and favourable lipid profile changes—effects not consistently observed with naltrexone-bupropion combinations [3]. However, Mysimba may suit patients who prefer oral medication or have contraindications to GLP-1 therapies.

At Cured Pharmacy, our superintendent pharmacist Tarun Kumar (GPhC 2233073) and clinical team assess individual patient factors including BMI, comorbidities, medication history, and personal preferences to recommend the most appropriate weight loss intervention. This personalised approach ensures treatment aligns with both clinical guidelines and patient lifestyle.

Who Benefits Most from Each Treatment?

Mysimba may be more suitable for patients who strongly prefer oral medication, have needle phobia, or have contraindications to GLP-1 therapies such as personal or family history of medullary thyroid carcinoma. Conversely, semaglutide-based treatments like Wegovy typically suit patients seeking maximum weight loss efficacy, those with type 2 diabetes or prediabetes, and individuals comfortable with weekly injections.

Side Effect Profiles: Mysimba vs Ozempic Safety

Mysimba's most common side effects include nausea (32% of patients), constipation, headache, dizziness, and insomnia, particularly during dose escalation [1]. Serious but rare risks include seizures (occurring in approximately 0.1% of patients), elevated blood pressure, and psychiatric effects including mood changes. Regular blood pressure monitoring is essential during Mysimba treatment.

Ozempic and other semaglutide formulations primarily cause gastrointestinal effects: nausea (20-44% depending on dose), vomiting, diarrhoea, and constipation, typically improving after several weeks as the body adjusts [2]. Rare but serious risks include pancreatitis, gallbladder disease, and potential thyroid C-cell tumours (observed in rodent studies but not confirmed in humans).

Both medications require clinical monitoring and are unsuitable during pregnancy or breastfeeding. Your UK prescriber will review your complete medical history, current medications, and risk factors before prescribing either treatment, ensuring the benefits outweigh potential risks in your individual case.

Dosing Schedules and Treatment Duration

Mysimba follows a structured escalation: one tablet daily (week 1), one tablet twice daily (week 2), two tablets morning and one evening (week 3), then full maintenance dose of two tablets twice daily from week 4 onwards. Patients should take tablets with food and avoid evening doses close to bedtime due to potential insomnia.

Ozempic begins at 0.25mg weekly for four weeks (an initiation dose, not therapeutic), increasing to 0.5mg weekly, with further escalation to 1mg or 2mg based on tolerability and clinical response. Wegovy uses a different escalation schedule optimised for weight loss, starting at 0.25mg and increasing monthly to a maximum maintenance dose of 2.4mg weekly [3].

Treatment duration varies by individual response and clinical goals. NICE guidelines suggest reviewing weight loss medications at 3-6 months; if patients haven't achieved at least 5% weight loss, alternative approaches should be considered. Many patients continue treatment for 12-24 months or longer under ongoing prescriber supervision.

What Happens When You Stop Treatment?

Weight regain is common after discontinuing either medication, as neither addresses the underlying biological drivers of obesity permanently. Clinical trials show average weight regain of 5-7% within 12 months of stopping GLP-1 therapies [3]. Successful long-term weight maintenance requires sustained lifestyle modifications including dietary changes, regular physical activity, and often continued pharmacological support under medical supervision.

Accessing Weight Loss Treatment Through Cured Pharmacy

At Cured Pharmacy, we offer transparent access to clinically proven weight loss treatments including Wegovy (semaglutide) from £79.00. Our streamlined online consultation takes under three minutes and is reviewed by UK-registered prescribers who assess your medical history, current health status, and treatment goals.

All medications dispensed are genuine UK-licensed products sourced through regulated supply chains, never grey imports or unlicensed formulations. Your prescription is fulfilled by our GPhC-registered pharmacy (9012511) with discreet packaging and reliable delivery across the UK. Prices are displayed upfront before consultation, with no hidden fees or subscription traps.

We don't currently stock Mysimba or Ozempic single pens, but Wegovy provides superior weight loss efficacy using the same active ingredient as Ozempic at doses specifically optimised for obesity treatment. Our clinical team will discuss whether semaglutide-based therapy aligns with your medical profile and weight management objectives during your confidential assessment.

Scientific References

1. Greenway, F. L., et al. (2010). Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 376(9741), 595–605. https://doi.org/10.1016/S0140-6736(10)60888-4
2. Davies, M., et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0
3. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals and depend on multiple factors including adherence to lifestyle modifications.